Phase 2 trial in 800 toddlers aged 12-15 months: an investigational varicella vaccine (VNS) at low, medium or high potency gave antibody levels generally comparable to a licensed control vaccine (seroresponse 93.6-98.7% vs 98.1%), with similar adverse event rates.
RCTn = 800
Habib et al. Immunogenicity and safety of an investigational varicella zoster vaccine in toddlers aged 12-15 months: results of a phase II, controlled, randomized trial